BlackRock’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-21,940
| Closed | -$100K | – | 5628 |
|
|
2025
Q3 | $100K | Buy |
21,940
+21,875
| +33,654% | +$97K | ﹤0.01% | 4826 |
|
|
2025
Q2 | $81 | Hold |
65
| – | – | ﹤0.01% | 5414 |
|
|
2025
Q1 | $87 | Hold |
65
| – | – | ﹤0.01% | 5382 |
|
|
2024
Q4 | $95 | Hold |
65
| – | – | ﹤0.01% | 5352 |
|
|
2024
Q3 | $435 | Hold |
65
| – | – | ﹤0.01% | 5162 |
|
|
2024
Q2 | $488 | Hold |
65
| – | – | ﹤0.01% | 5221 |
|
|
2024
Q1 | $967 | Sell |
65
-9
| -12% | -$121 | ﹤0.01% | 5206 |
|
|
2023
Q4 | $1.03K | Hold |
74
| – | – | ﹤0.01% | 5268 |
|
|
2023
Q3 | $1.7K | Hold |
74
| – | – | ﹤0.01% | 5305 |
|
|
2023
Q2 | $6.42K | Hold |
74
| – | – | ﹤0.01% | 5289 |
|
|
2023
Q1 | $4.72K | Hold |
74
| – | – | ﹤0.01% | 5376 |
|
|
2022
Q4 | $15.1K | Hold |
74
| – | – | ﹤0.01% | 5408 |
|
|
2022
Q3 | $19K | Hold |
74
| – | – | ﹤0.01% | 5522 |
|
|
2022
Q2 | $51K | Hold |
74
| – | – | ﹤0.01% | 5408 |
|
|
2022
Q1 | $69K | Hold |
74
| – | – | ﹤0.01% | 5359 |
|
|
2021
Q4 | $76K | Hold |
74
| – | – | ﹤0.01% | 5338 |
|
|
2021
Q3 | $111K | Hold |
74
| – | – | ﹤0.01% | 5115 |
|
|
2021
Q2 | $290K | Sell |
74
-30
| -29% | -$131K | ﹤0.01% | 4817 |
|
|
2021
Q1 | $575K | Buy |
104
+4
| +4% | +$25.3K | ﹤0.01% | 4589 |
|
|
2020
Q4 | $550K | Buy |
100
+2
| +2% | +$12.7K | ﹤0.01% | 4336 |
|
|
2020
Q3 | $619K | Hold |
98
| – | – | ﹤0.01% | 4223 |
|
|
2020
Q2 | $881K | Buy |
+98
| New | +$1.14M | ﹤0.01% | 4071 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 4796 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 4773 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 4739 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 4747 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4604 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4631 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4624 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4611 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4466 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4514 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4551 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4582 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4508 |
|
Other funds holding SONN
BlackRock's SONN Position: Q4 2025 in Review
BlackRock sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 21,940 shares — an estimated $100K sold.
BlackRock first reported a position in SONN in Q2 2020 and held it in 22 quarters. The position peaked at $881K in Q2 2020. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- BlackRock reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 21,940 Sonnet BioTherapeutics shares in Q4 2025, an estimated $100K.
- BlackRock first reported a position in Sonnet BioTherapeutics in Q2 2020 and held it in 22 quarters.
- BlackRock's Sonnet BioTherapeutics position peaked at $881K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.